Skip to content
value.today

Pear Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2013
Total raised
$255 M
4 rounds on record
Latest round
$132 M
Dec 2020
First round on record
Jan 2016
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pear Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$132 MNo. 4$50 to $250 million

Pear Therapeutics, Inc.: Raise no. 4, Dec 2020

Investors in this round

22 investors had bought by the notice of Mar 2, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$132 M of $132 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Guiffre · Executive Officer
  • Corey McCann · Executive Officer, Director
  • Julia Strandberg · Executive Officer
  • Ronan O'Brien · Executive Officer
  • Yuri Maricich · Executive Officer
  • Andrew Schwab · Director
  • Elena Viboch · Director · Ms. Viboch was elected as a Director subsequent to the Date of First Sale.
  • Nancy Schlichting · Director · Ms. Schlichting was elected as a Director subsequent to the Date of First Sale.
  • Timothy Petersen · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $31,999,996 of proceeds used to repurchase securities, resulting in $99,999,927 of gross proceeds after the repurchase (before expenses).”

Signed by Christopher Guiffre, Cfo & coo. Source: SEC Form D and 1 amendment, newest notice filed Mar 2, 2021. Read the notice at the SEC.

equitySEC
Dec 2018$64 MNo. 3$50 to $250 million

Pear Therapeutics, Inc.: Raise no. 3, Dec 2018

Investors in this round

21 investors had bought by the notice of Jan 4, 2019: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$64 M of $65 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex Waldron · Executive Officer
  • Christopher Guiffre · Executive Officer
  • Corey McCann · Executive Officer, Director
  • Jeremy Gilbert · Executive Officer
  • Yuri Maricich · Executive Officer
  • Andrew Schwab · Director
  • Hongjie Hu · Director
  • Timothy Petersen · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Guiffre, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 4, 2019. Read the notice at the SEC.

equitySEC
Dec 2017$46 MNo. 2$10 to $50 million

Pear Therapeutics, Inc.: Raise no. 2, Dec 2017

Investors in this round

14 investors had bought by the notice of Jan 12, 2018: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$46 M of $51 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antoun Nabhan · Executive Officer
  • Christopher Guiffre · Executive Officer
  • Corey McCann · Executive Officer, Director
  • Andrew Schwab · Director
  • Timothy Petersen · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$4,999,999 reserved for sale at a second closing of the offering.”

Signed by Corey McCann, President and CEO. Source: SEC Form D, newest notice filed Jan 12, 2018. Read the notice at the SEC.

equitySEC
Jan 2016$12 MNo. 1$10 to $50 million

Pear Therapeutics, Inc.: Raise no. 1, Jan 2016

Investors in this round

13 investors had bought by the notice of Feb 9, 2016: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $20 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Corey McCann · Executive Officer, Director
  • Andrew J. Schwab · Director
  • Tim J. Petersen · Director
  • Zack J. Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Corey McCann, President and CEO. Source: SEC Form D, newest notice filed Feb 9, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pear Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2021

That is all the official record says: Pear Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pear Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pear Therapeutics, Inc.
NameRoleNamed in
Christopher GuiffreExecutive officerMar 2021
Corey McCannExecutive officerMar 2021
Julia StrandbergExecutive officerMar 2021
Ronan O'BrienExecutive officerMar 2021
Yuri MaricichExecutive officerMar 2021
Alex WaldronExecutive officerJan 2019
Jeremy GilbertExecutive officerJan 2019
Antoun NabhanExecutive officerJan 2018
Andrew SchwabDirectorMar 2021
Corey McCannDirectorMar 2021
Elena VibochMs. Viboch was elected as a Director subsequent to the Date of First Sale.Mar 2021
Nancy SchlichtingMs. Schlichting was elected as a Director subsequent to the Date of First Sale.Mar 2021
Timothy PetersenDirectorMar 2021
Zack LynchDirectorMar 2021
Hongjie HuDirectorJan 2019
Andrew J. SchwabDirectorFeb 2016
Tim J. PetersenDirectorFeb 2016
Zack J. LynchDirectorFeb 2016